Clinical Trial Update: Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing whether twice-daily 60 mg AZD9668 over 12 weeks can influence structural changes in the airways of COPD patients, as measured by MSCT. R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD9668 (AZD9668)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED | Results posted: 2012-07-25